Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CMA1 | P23946 | 7/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CTRC | Q99895 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16290821 | 1.00 | KCNH2 (0.62) | KCNH2CYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL20952514 | 1.00 | KCNH2 (0.62) | KCNH2CYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL20952254 | 0.94 | KCNH2 (0.62) | KCNH2CYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL475258 | 0.94 | KCNH2 (0.62) | KCNH2CYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL16291124 | 0.94 | KCNH2 (0.62) | KCNH2CYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL475256 | 0.94 | KCNH2 (0.62) | KCNH2CYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL24732245 | 0.93 | KCNH2 (0.60) | KCNH2CYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL10223689 | 0.92 | KCNH2 (0.58) | KCNH2CYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL10222828 | 0.91 | KCNH2 (0.58) | KCNH2CYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL16199243 | 0.91 | KCNH2 (0.61) | KCNH2CYP2C9CYP2C19CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102427729-A | Inhibitors of hepatitis c virus replication | MERCK SHARP & DOHME | 2012-04-25 | — | — | CN | claimed |
| US-20120083483-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP (NJ) | 2012-04-05 | — | — | US | claimed |
| US-20220356182-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2022-11-10 | — | — | US | disclosed |
| US-20220356182-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2022-11-10 | — | — | US | disclosed |
| US-11053243-B2 | Inhibitors of hepatitis C virus replication | MERCK SHARP & DOHME CORP. (US) | 2021-07-06 | — | — | US | disclosed |
| US-11053243-B2 | Inhibitors of hepatitis C virus replication | MERCK SHARP & DOHME CORP. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200262836-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2020-08-20 | — | — | US | disclosed |
| US-20200262836-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2020-08-20 | — | — | US | disclosed |
| US-20190127365-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2019-05-02 | — | — | US | disclosed |
| US-20190127365-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2019-05-02 | — | — | US | disclosed |
| US-20170008906-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| US-9090661-B2 | Inhibitors of hepatitis C virus replication | MERCK SHARP & DOHME CORP. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090661-B2 | Inhibitors of hepatitis C virus replication | MERCK SHARP & DOHME CORP. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140371138-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2014-12-18 | — | — | US | disclosed |
| US-20140371138-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2014-12-18 | — | — | US | disclosed |
| US-20140371138-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2014-12-18 | — | — | US | disclosed |
| US-8871759-B2 | Inhibitors of hepatitis C virus replication | MERCK SHARP & DOHME CORP. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871759-B2 | Inhibitors of hepatitis C virus replication | MERCK SHARP & DOHME CORP. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20120083483-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP (NJ) | 2012-04-05 | — | — | US | disclosed |
| US-20120083483-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP (NJ) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200262836-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | KCNH2 4621/4885CYP2C9 2551/4885CYP2C19 3129/4885 |
| US-20120083483-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | KCNH2 4621/4885CYP2C9 2551/4885CYP2C19 3129/4885 |
| US-20140371138-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | KCNH2 4621/4885CYP2C9 2551/4885CYP2C19 3129/4885 |
| US-20170008906-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | KCNH2 4621/4885CYP2C9 2551/4885CYP2C19 3129/4885 |
| US-11053243-B2 | Inhibitors of hepatitis C virus replication | HAVCR2, HCCS, EIF2AK2 | KCNH2 4621/4885CYP2C9 2551/4885CYP2C19 3129/4885 |
| US-20190127365-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | KCNH2 4621/4885CYP2C9 2551/4885CYP2C19 3129/4885 |
| US-20220356182-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | KCNH2 4621/4885CYP2C9 2551/4885CYP2C19 3129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.